Biological and immunological characteristics of lipooligosaccharide-based conjugate vaccines for serotype C Moraxella catarrhalis

Infection and Immunity

Volumn 75, Issue 6, 2007, Pages 2974-2980

  Yu, Shengqing ^a   Gu, Xin Xing ^a,b  

^a NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA TOXIN; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; LIPOOLIGOSACCHARIDE; RABBIT ANTISERUM; TETANUS TOXOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DETOXIFICATION; DRUG CONJUGATION; FEMALE; IMMUNOGENICITY; MORAXELLA CATARRHALIS; MOUSE; NONHUMAN; OTITIS MEDIA; PRIORITY JOURNAL; RABBIT; RESPIRATORY TRACT INFECTION; SEROTYPE;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; MORAXELLA (BRANHAMELLA) CATARRHALIS; MORAXELLACEAE INFECTIONS; VACCINES, CONJUGATE;

EID: 34249914222     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.01915-06     Document Type: Article

References (43)

1. Adlowitz, D. G., T. Hiltke, A. J. Lesse, and T. F. Murphy. 2004. Identification and characterization of outer membrane proteins G1a and G1b of Moraxella catarrhalis. Vaccine 22:2533-2540.
2. Bennett, K. E., M. P. Haggard, P. A. Silva, and I. A. Stewart. 2001. Behaviour and developmental effects of otitis media with effusion into the teens. Arch. Dis. Child. 85:91-95.
3. Catlin, B. W. 1990. Branhamella catarrhalis: an organism gaining respect as a pathogen. Clin. Microbiol. Rev. 3:293-320.
4. Cripps, A. W., and D. C. Otczyk. 2006. Prospects for a vaccine against otitis media. Expert Rev. Vaccines 5:517-534.
5. Daoud, A., F. Abuekteish, and H. Masaadeh. 1996. Neonatal meningitis due to Moraxella catarrhalis and review of the literature. Ann. Trop. Paediatr. 16:199-201.
6. Doern, G. V. 1986. Branhamella catarrhalis - an emerging human pathogen. Diagn. Microbiol. Infect. Dis. 4:191-201.
7. Dubois, M., H. Gillis, J. K. Hamilton, A. A. Rebers, and R. Smith. 1956. Colorimetric method for the determination of sugars and related substances. Anal. Biochem. 28:250-256.
8. Easton D. M., A. Smith, S. G. Gallego, A. R. Foxwell, A. W. Cripps, and J. M. Kyd. 2005. Characterization of a novel porin protein from Moraxella catarrhalis and identification of an immunodominant surface loop. J. Bacteriol. 187:6528-6535.
9. Faden, H., J. Hong, and T. F. Murphy. 1992. Immune response to outer membrane antigens of Moraxella catarrhalis in children with otitis media. Infect. Immune. 60:3824-3829.
10. Forsgren, A., M. Brant, M. Karamehmedovic, and K. Riesbeck. 2003. The immunoglobulin D-binding protein MID from Moraxella catarrhalis is also an adhesin. Infect. Immun. 71:3302-3309.
11. Gu, X.-X., J. Chen, S. J. Barenkamp, J. B. Robbins, C.-M. Tsai, D. J. Lim, and J. Battery. 1998. Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis. Infect. Immun. 66:1891-1897.
12. Gu, X.-X., and C.-M. Tsai. 1993. Preparation, characterization, and immunogenicity of meningococcal lipooligosaccharide-derived oligosaccharide-protein conjugate. Infect. Immun. 61:1873-1880.
13. Gu, X.-X., C.-M. Tsai, T. Ueyama, S. J. Barenkamp, J. B. Robbins, and D. J. Lim. 1996. Synthesis, characterization, and immunological properties of detoxified lipooligosaccharide from nontypeable Haemophilus influenzae conjugated to proteins. Infect. Immun. 64:4047-4053.
14. Hager, H., A. Verghese, S. Alvarez, and S. L. Berk. 1987. Branhamella catarrhalis respiratory infections. Rev. Infect. Dis. 9:1140-1149.
15. Hoi-Dang, A. B., B. C. Brive-Le, M. Barthelemy, and R. Labia. 1978. Novel beta-lactamase from Branhamella catarrhalis. Ann. Microbiol. (Paris) 129B:397-406.
16. Holme, T., M. Rahman, P. E. Jansson, and G. Widmalm. 1999. The lipopolysaccharide of Moraxella catarrhalis structural relationships and antigenic properties. Eur. J. Biochem. 265:524-529.
17. Hu, W.-G., J. Chen, J. F. Battey, and X.-X. Gu. 2000. Enhancement of clearance of bacteria from murine lungs by immunization with detoxified lipooligosaccharide from Moraxella catarrhalis conjugated to proteins. Infect. Immun. 68:4980-4985.
18. Hu, W.-G., J. Chen, J. C. Mc Michael, and X.-X. Gu. 2001. Functional characteristics of a protective monoclonal antibody against serotype A and C lipooligosaccharides from Moraxella catarrhalis. Infect. Immun. 69:1358-1363.
19. Hu, W.-G., J. Berry, J. Chen, and X.-X. Gu. 2004. Exploration of Moraxella catarrhalis outer membrane proteins, CD and UspA, as new carriers for lipooligosaccharide-based conjugates. FEMS Immunol. Med. Mic. 41:109-115.
20. Jiao, X., H. Takashi, Y. Hou, and X.-X. Gu. 2002. Specific immune responses and enhancement of murine pulmonary clearance of Moraxella catarrhalis by intranasal immunization with a detoxified lipooligosaccharide conjugate vaccine. Infect. Immun. 70:5982-5989.
21. Karalus, R., and A. Campagnari. 2000. Moraxella catarrhalis: a review of an important human mucosal pathogen. Microbes Infect. 2:547-559.
22. Klein, J. O. 1994. Current issues in upper respiratory tract infections in infants and children: rationale for antibacterial therapy. Pediatr. Infect. Dis. J. 13:S5-S9. (Discussion, 13:S20-S22.)
23. Klein, J. O. 1994. Otitis media. Clin. Infect. Dis. 19:823-833.
24. McMichael, J. C. 2000. Vaccines for Moraxella catarrhalis. Vaccine 19:S101-S107.
25. McMichael, J. C., and B. A. Green. 2003. Vaccines for Moraxella catarrhalis and non-typeable Haemophilus influenzae. Curr. Opin. Investig. Drugs 4:953-958.
26. Murphy, T. F. 1996. Branhamella catarrhalis: epidemiology, surface antigenic structure, and immune response. Microbiol. Rev. 60:267-279.
27. Murphy, T. F. 2005. Vaccine development for non-typeable Haemophilus influenzae and Moraxella catarrhalis: progress and challenges. Expert Rev. Vaccines 4:843-853.
28. Peng, D., B. P. Choudhury, R. S. Petralia, R. W. Carlson, and X.-X. Gu. 2005. Roles of 3-deoxy-D-manno-2-octulosonic acid transferase from Moraxella catarrhalis in lipooligosaccharide biosynthesis and virulence. Infect. Immun. 73:4222-4230.
29. Rahman, M., and T. Holme. 1996. Antibody response in rabbits to serotype-specific determinants in lipopolysaccharides from Moraxella catarrhalis. J. Med. Microbiol. 44:348-354.
30. Rahman, M., T. Holme, I. Jonsson, and A. Krook. 1995. Lack of serotype-specific antibody response to lipopolysaccharide antigens of Moraxella catarrhalis during lower respiratory tract infection. Eur. J. Clin. Microbiol. Infect. Dis. 14:297-304.
31. Ruuskanen, O., and T. Heikkinen. 1994. Otitis media: etiology and diagnosis. Pediatr. Infect. Dis. J. 13:S23-S26.
32. Shiloach, J., and J. B. Kaufman. 1999. The combined use of expanded bed volume adsorption and gradient elution for capture and partial purification of mutant diphtheria toxin (CRM9) from Corynebacterium diphtheriae. Sep. Sci. Technol. 34:29-40.
33. Smith, P. K., R. I. Krohn, G. T. Hermanson, A. K. Mallia, F. H. Gartner, M. D. Provenzano, E. K. Fujimoto, N. M. Goeke, B. J. Olson, and D. C. Klenk. 1985. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150:76-85.
34. Tanaka, H., K. Oishi, F. Sonoda, A. Iwagaki, T. Nagatake, and K. Matsumoto. 1992. Biochemical analysis of lipopolysaccharides from respiratory pathogenic Branhamella catarrhalis strains and the role of anti-LPS antibodies in Branhamella respiratory infections. J. Jpn. Assoc. Infect. Dis. 66:709-715.
35. Teele, D. W., J. O. Klein, and B. Rosner. 1989. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J. Infect. Dis. 160:83-94.
36. Timpe, J. M., M. M. Holm, S. L. Vanlerberg, V. Basrur, and E. R. Lafontaine. 2003. Identification of a Moraxella catarrhalis outer membrane protein exhibiting both adhesin and lipolytic activities. Infect. Immun. 71:4341-4350.
37. Tsai, C. M., and C. E. Frasch. 1982. A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Anal. Biochem. 119:115-119.
38. Unhanand, M., I. Maciver, O. Ramilo, O. Arencibia-Mireles, J. C. Argyle, G. H. McCracken, and E. J. Hansen. 1992. Pulmonary clearance of Moraxella catarrhalis in an animal model. J. Infect. Dis. 165:644-650.
39. Vaneechoutte, M., G. Verschraegen, G. Claeys, and A. M. van den Abeele. 1990. Serological typing of Branhamella catarrhalis strains on the basis of lipooligosaccharide antigens. J. Clin. Microbiol. 28:182-187.
40. Verduin C. M., C. Hol, A. Fleer, H. van Dijk, and A. van Belkum. 2002. Moraxella catarrhalis: from emerging to established pathogen. Clin. Microbiol. Rev. 15:125-144.
41. Warburg, O., and W. Christian. 1942. Isolation and crystallization of enolase. Biochem. Z. 310:384-421.
42. W.H.O. Expert Committee on Biological Standardization. 1991. Requirements for Haemophilus type b conjugate vaccines. WHO Tech. Rep. Ser. 814:15-37.
43. Yu, S., and X.-X. Gu. 2005. Synthesis and characterization of lipooligosaccharide-based conjugate vaccines for serotype B Moraxella catarrhalis. Infect. Immun. 73:2790-2796.